A clinical-stage biopharmaceutical developer focused on targeted cancer therapies built around small‑molecule drug conjugates and radioligand treatments. Its pipeline centered on precision medicines designed to deliver radiation or cytotoxic agents directly to tumor cells, including PSMA‑targeted th...
1 member of Congress has disclosed 9 trades in Endocyte, Inc. (ECYT), a Healthcare company. The buy/sell breakdown shows 5 purchases versus 4 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-04-16 | CHARLES J. "CHUCK" FLEISCHMANN | sell | $1K – $15K |
| 2025-04-16 | CHARLES J. "CHUCK" FLEISCHMANN | sell | $1K – $15K |
| 2023-01-23 | CHARLES J. "CHUCK" FLEISCHMANN | buy | $1K – $15K |
| 2022-10-19 | CHARLES J. "CHUCK" FLEISCHMANN | sell | $1K – $15K |
| 2022-07-21 | CHARLES J. "CHUCK" FLEISCHMANN | sell | $1K – $15K |
| 2021-01-21 | CHARLES J. "CHUCK" FLEISCHMANN | buy | $1K – $15K |
| 2021-01-21 | CHARLES J. "CHUCK" FLEISCHMANN | buy | $15K – $50K |
| 2020-07-23 | CHARLES J. "CHUCK" FLEISCHMANN | buy | $1K – $15K |
| 2020-04-01 | CHARLES J. "CHUCK" FLEISCHMANN | buy | $1K – $15K |